For the quarter ending 2025-12-31, BNTC made $14,917K in revenue. -$11,837K in net income. Net profit margin of -79.35%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Royalties and license fees | - | - | 0 | - |
| Total revenues | 0 | 0 | - | - |
| Research and development | 5,834 | 3,370 | 3,695 | 5,980 |
| General and administrative | 7,543 | 6,433 | 13,481 | 4,208 |
| Total operating expenses | 13,377 | 9,803 | 17,176 | 10,188 |
| Loss from operations | -13,377 | -9,803 | -17,176 | -10,188 |
| Foreign currency transaction gain (loss) | 131 | -89 | 119 | 11 |
| Interest income, net | 1,390 | 1,011 | 1,036 | 823 |
| Other income (expense), net | 19 | -84 | -63 | - |
| Gain on extinguishment of liabilities | 0 | - | 0 | - |
| Unrealized loss on investment | - | - | 0 | - |
| Total other income, net | 1,540 | 838 | 1,029 | 834 |
| Net loss | -11,837 | -8,965 | -16,147 | -9,354 |
| Unrealized foreign currency translation gain (loss) | - | 89 | - | - |
| Total other comprehensive income (loss) | - | 89 | - | - |
| Total comprehensive loss | - | -8,876 | - | - |
| Net loss attributable to common shareholders | -11,837 | - | - | - |
| Earnings per share, basic | -0.26 | -0.22 | 0 | -0.24 |
| Earnings per share, diluted | -0.26 | -0.22 | 0 | -0.24 |
| Weighted average number of shares outstanding, basic | 45,970,516 | 41,521,280 | -35,110,047 | 38,599,453 |
| Weighted average number of shares outstanding, diluted | 45,970,516 | 41,521,280 | -35,110,047 | 38,599,453 |
Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc. (BNTC)